Advancing a class on top of statins
Investors & Media

2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016
DateTitle  
01/17/18Gemphire Completes Patient Enrollment in INDIGO-1 Trial in Severe Hypertriglyceridemia (SHTG) Patients
On Track to Report Top-Line Data from Phase 2b Trial in Second Quarter of 2018 LIVONIA, Mich., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), today announced that it has achieved its enrollment goal of 90 subjects across 39 sites in its Phase 2b INDIGO-1 trial investigating g... 
Download PDFPrinter Friendly Version